ARDX Ardelyx Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARDX

Price (delayed)

$4

Market cap

$825.97M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.42

Enterprise value

$766.29M

Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate ...

Highlights
The EPS has surged by 72% year-on-year and by 51% since the previous quarter
The net income has soared by 58% YoY and by 41% from the previous quarter
The company's quick ratio fell by 9% YoY but it rose by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ardelyx.com
Peers: OPK AMGN ABT

Key stats

What are the main financial stats of ARDX
Market
Shares outstanding
206.49M
Market cap
$825.97M
Enterprise value
$766.29M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.63
Price to sales (P/S)
12.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.69
Earnings
Revenue
$52.16M
EBIT
-$63.8M
EBITDA
-$59.2M
Free cash flow
-$68.3M
Per share
EPS
-$0.42
Free cash flow per share
-$0.43
Book value per share
$0.52
Revenue per share
$0.33
TBVPS
$1.2
Balance sheet
Total assets
$190.07M
Total liabilities
$91.74M
Debt
$36.46M
Equity
$98.33M
Working capital
$88M
Liquidity
Debt to equity
0.37
Current ratio
2.34
Quick ratio
2.01
Net debt/EBITDA
1.01
Margins
EBITDA margin
-113.5%
Gross margin
92.1%
Net margin
-128.9%
Operating margin
-122.2%
Efficiency
Return on assets
-45.1%
Return on equity
-95.2%
Return on invested capital
-93.3%
Return on capital employed
-51.3%
Return on sales
-122.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARDX stock price

How has the Ardelyx stock price performed over time
Intraday
-1.48%
1 week
-1.23%
1 month
35.59%
1 year
263.64%
YTD
40.35%
QTD
40.35%

Financial performance

How have Ardelyx's revenue and profit performed over time
Revenue
$52.16M
Gross profit
$48.04M
Operating income
-$63.76M
Net income
-$67.21M
Gross margin
92.1%
Net margin
-128.9%
Ardelyx's net margin has surged by 92% YoY and by 90% QoQ
ARDX's operating margin has surged by 92% year-on-year and by 90% since the previous quarter
The company's operating income has surged by 59% YoY and by 43% QoQ
The net income has soared by 58% YoY and by 41% from the previous quarter

Growth

What is Ardelyx's growth rate over time

Valuation

What is Ardelyx stock price valuation
P/E
N/A
P/B
7.63
P/S
12.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.69
The EPS has surged by 72% year-on-year and by 51% since the previous quarter
ARDX's P/B is 154% above its 5-year quarterly average of 3.0 and 154% above its last 4 quarters average of 3.0
Ardelyx's equity has increased by 47% QoQ and by 19% YoY
The price to sales (P/S) is 88% lower than the 5-year quarterly average of 98.4 and 41% lower than the last 4 quarters average of 20.5

Efficiency

How efficient is Ardelyx business performance
The return on sales has surged by 92% year-on-year and by 90% since the previous quarter
Ardelyx's ROA has increased by 48% YoY and by 45% from the previous quarter
Ardelyx's ROE has increased by 44% from the previous quarter and by 38% YoY
The company's return on invested capital rose by 41% QoQ and by 35% YoY

Dividends

What is ARDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARDX.

Financial health

How did Ardelyx financials performed over time
ARDX's total assets is 107% greater than its total liabilities
ARDX's total liabilities is up by 36% year-on-year and by 18% since the previous quarter
ARDX's total assets is up by 31% since the previous quarter and by 27% year-on-year
Ardelyx's debt is 63% lower than its equity
Ardelyx's equity has increased by 47% QoQ and by 19% YoY
Ardelyx's debt to equity has decreased by 34% QoQ and by 33% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.